GSK (LON:GSK – Get Rating)‘s stock had its “buy” rating restated by equities research analysts at Shore Capital in a note issued to investors on Friday, Digital Look reports.
GSK has been the subject of several other reports. Berenberg Bank restated a “buy” rating and set a GBX 1,730 ($21.65) price target on shares of GSK in a research report on Monday, June 5th. JPMorgan Chase & Co. restated an “underweight” rating and set a GBX 1,400 ($17.52) price target on shares of GSK in a research report on Wednesday. Barclays reiterated an “equal weight” rating and set a GBX 1,450 ($18.14) target price on shares of GSK in a report on Thursday, April 27th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,700 ($21.27) target price on shares of GSK in a report on Thursday, June 8th. Finally, Citigroup reiterated a “neutral” rating on shares of GSK in a report on Tuesday, May 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, GSK currently has a consensus rating of “Hold” and a consensus target price of GBX 1,573.33 ($19.69).
GSK Stock Performance
LON GSK opened at GBX 1,383.60 ($17.31) on Friday. The company has a 50-day simple moving average of GBX 1,436.98 and a two-hundred day simple moving average of GBX 1,436.36. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 184.80. GSK has a 12-month low of GBX 1,280.92 ($16.03) and a 12-month high of GBX 2,280.50 ($28.53). The firm has a market cap of £56.59 billion, a price-to-earnings ratio of 1,269.36, a PEG ratio of 1.29 and a beta of 0.28.
Insiders Place Their Bets
In related news, insider Iain Mackay acquired 200 shares of the stock in a transaction on Tuesday, April 18th. The stock was acquired at an average cost of GBX 1,493 ($18.68) per share, for a total transaction of £2,986 ($3,736.24). In other GSK news, insider Iain Mackay bought 200 shares of the stock in a transaction dated Tuesday, April 18th. The stock was purchased at an average cost of GBX 1,493 ($18.68) per share, for a total transaction of £2,986 ($3,736.24). Also, insider Jonathan Symonds purchased 2,100 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The stock was bought at an average price of GBX 1,399 ($17.51) per share, for a total transaction of £29,379 ($36,760.51). Insiders purchased 2,318 shares of company stock worth $3,262,006 over the last three months. Company insiders own 1.75% of the company’s stock.
About GSK
(Get Rating)
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider GSK, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and GSK wasn’t on the list.
While GSK currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here